Ligand News and Research

RSS

Alnylam releases positive top-line data from ALN-TTRsc Phase I trial for TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive top-line results from its ongoing Phase I trial of ALN-TTRsc, a subcutaneously administered RNAi therapeutic targeting the transthyretin gene for the treatment of TTR-mediated amyloidosis.

12 Jul 2013

Drugs used to control BP associated with lower risk of heart failure in diabetic patients

Two drugs, telmisartan and valsartan, which are used to reduce blood pressure in people with diabetes, are associated with a lower risk of hospitalization for heart attack, stroke or heart failure, according to a study published in CMAJ (Canadian Medical Association Journal).

9 Jul 2013

VBL Therapeutics publishes VB-201 pre-clinical data in journal of Atherosclerosis

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, announced today the publication of pre-clinical data for VB-201 in the journal of Atherosclerosis.

8 Jul 2013

Assay identifies T cells as most capable of fighting infections and cancers

The idea of fighting infections and even cancers by inducing protective immune responses may now be a step closer to clinical practice. Researchers have removed a major obstacle to widespread use of so-called adoptive transfer therapy, in which a patient receives "killer" immune cells targeting a disease agent. Existing technologies can easily provide T cells that will recognize a specific antigen, but it has been challenging to identify individual cells most likely to succeed in fighting the disease - until now.

4 Jul 2013

Bioapplications of nanoparticles: an interview with Dr Catherine Berry, University of Glasgow

These particles are all classed as inorganic particles, which can all be utilised in biomedical applications. They differ in terms of their inherent material and size dependent physiochemical properties, for example, their optical and magnetic properties.

18 Jun 2013

Pyrvinium pamoate inhibits drug-resistant prostate cancer

A new drug called pyrvinium pamoate inhibits aggressive forms of prostate cancer that are resistant to standard drugs, according to a study conducted in an animal model. The results will be presented Monday at The Endocrine Society's 95th Annual Meeting in San Francisco.

18 Jun 2013

Mount Sinai researchers present several new studies at ENDO 2013

Researchers from the Icahn School of Medicine at Mount Sinai will present several new studies at ENDO 2013, The Endocrine Society's Annual Meeting & Expo from June 15-18 in San Francisco.

17 Jun 2013

People with narcolepsy have increased number of neurons that produce histamine

A new study provides surprising evidence that people with narcolepsy have an increased number of neurons that produce histamine, suggesting that histamine signaling may be a novel therapeutic target for this potentially disabling sleep disorder.

4 Jun 2013

Researchers develop RNA aptamers that inhibit HCV replication

Treatments against hepatitis C virus have only been partially successful. A major problem is that antivirals generate drug resistance. Now Seong-Wook Lee of Dankook University, Yongin, Republic of Korea and his collaborators have developed agents that bind to the business end of a critical protein, disabling it so successfully that no resistance has arisen.

3 Jun 2013

Ruthenium complexes could pave way for cancer treatments, say UT Arlington researchers

A team of UT Arlington researchers has identified two ruthenium-based complexes they believe could pave the way for treatments that control cancer cell growth more effectively and are less toxic for patients than current chemotherapies.

30 May 2013

New TGT method helps detect and measure mechanics of single-molecule interaction

Cells in the human body do not function in isolation. Living cells rely on communication with their environment-neighboring cells and the surrounding matrix-to activate a wide range of cellular functions, including reproduction of new cells, differentiation of stem cells into distinct cell types, cell adhesion, and migration of white blood cells to fight bodily infections.

24 May 2013

Cognoptix' SAPPHIRE II eye test identifies Alzheimer's disease patients via Ab signature in the eyes

Cognoptix, an emerging medical device company, announced today that its SAPPHIRE II eye test identified Alzheimer's disease patients via a beta amyloid ("Ab") signature in their eyes in a 10-subject proof-of-concept clinical trial.

23 May 2013

Emory University researchers identify a protein that stimulates orphan receptors in the brain

Researchers at Emory University have identified a protein that stimulates a pair of "orphan receptors" found in the brain, solving a long-standing biological puzzle and possibly leading to future treatments for neurological diseases.

22 May 2013

Alzheimer's disease: Researchers find new drug to prevent, treat the disease

Researchers at USC have found that a class of pharmaceuticals can both prevent and treat Alzheimer's Disease in mice.

22 May 2013

UC Davis scientists detect novel molecular target for multiple sclerosis

Working with lab mice models of multiple sclerosis, UC Davis scientists have detected a novel molecular target for the design of drugs that could be safer and more effective than current FDA-approved medications against MS.

17 May 2013

Trevena, Forest sign collaborative agreement to develop TRV027 for treatment of ADHF

Trevena, Inc., a clinical stage pharmaceutical company and the leader in the discovery and development of G-protein coupled receptor biased ligands, and Forest Laboratories Holding Limited, a subsidiary of Forest Laboratories Inc., an international pharmaceutical company, announced today that they have entered into a collaborative licensing option agreement for the development of TRV027, an AT1R biased-ligand that recently completed Phase 2a clinical trials.

9 May 2013

Scientists uncover unknown virulence factor in respiratory pathogen

To infect its host, the respiratory pathogen Pseudomonas aeruginosa takes an ordinary protein usually involved in making other proteins and adds three small molecules to turn it into a key for gaining access to human cells.

7 May 2013

Regeneron Pharmaceuticals expands ophthalmology portfolio

Regeneron Pharmaceuticals, Inc. today announced that it has expanded its ophthalmology portfolio by acquiring full exclusive rights to two families of novel antibodies invented at Regeneron and previously included in Regeneron's antibody collaboration with Sanofi.

3 May 2013

Berkeley Lab researchers unveil analytical technique for easy comparisons of proteins in solution

A revolutionary X-ray analytical technique that enables researchers at a glance to identify structural similarities and differences between multiple proteins under a variety of conditions has been developed by researchers with the U.S. Department of Energy's Lawrence Berkeley National Laboratory.

30 Apr 2013

Cognoptix provides update on multi-site clinical trial of SAPPHIRE II eye test

Cognoptix announced today that it has reached the halfway point in a multi-site clinical trial of its SAPPHIRE II eye test designed to identify Alzheimer's disease patients via a beta amyloid ("Ab") signature in their eyes.

10 Apr 2013